- Guardant Health ( NASDAQ: GH ) climbs 6.24% premarket on reporting preliminary, unaudited FY22 and Q4 results.
- FY22 revenue expected between $447M to $450M, an increase of 20% Y/Y, from prior view of $440M to $450M , vs consensus of $445.17M .
- The company reported 124,800 tests to clinical customers and 26,000 tests to biopharma customers in FY22, an increase of 42% and 40%, respectively.
- For Q4 revenue expected between $124M and $127M, an increase of between 15% and 17%, vs consensus of $122.69M .
- Reported 36,000 tests to clinical customers and 8,200 tests to biopharma customers in Q4, an increase of 41% and 24%, respectively.
- Cash, cash equivalents and marketable debt securities were $1.0B as of December 31, 2022.
-
“During the fourth quarter we delivered on a long-term ambition with the positive readout of our ECLIPSE trial. We are thrilled with the strong and positive feedback expressed by guideline members, key opinion leaders, and patient advocacy leaders about the performance of the Shield test in the ECLIPSE trial. Fueled by this success, we will expand this test to many other cancer types, including lung cancer, the leading cause of death from cancer,” said AmirAli Talasaz, co-founder and co-CEO.
For further details see:
Guardant health gains on guiding Q4 and FY22 revenue above estimates